##gff-version 3
##sequence-region Q9BXS4 1 323
Q9BXS4	UniProtKB	Signal peptide	1	35	.	.	.	Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q9BXS4	UniProtKB	Chain	36	323	.	.	.	ID=PRO_0000003003;Note=Transmembrane protein 59	
Q9BXS4	UniProtKB	Topological domain	36	238	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q9BXS4	UniProtKB	Transmembrane	239	259	.	.	.	Note=Helical;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q9BXS4	UniProtKB	Topological domain	260	323	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q9BXS4	UniProtKB	Motif	263	281	.	.	.	Note=ATG16L1-binding motif;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:23376921,ECO:0000269|PubMed:27273576;Dbxref=PMID:23376921,PMID:27273576	
Q9BXS4	UniProtKB	Modified residue	303	303	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9QY73	
Q9BXS4	UniProtKB	Glycosylation	90	90	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000305;evidence=ECO:0000305|PubMed:20427278;Dbxref=PMID:20427278	
Q9BXS4	UniProtKB	Natural variant	46	46	.	.	.	ID=VAR_063397;Note=A->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11042152;Dbxref=dbSNP:rs41294776,PMID:11042152	
Q9BXS4	UniProtKB	Mutagenesis	268	268	.	.	.	Note=Impaired ability to activate LC3. Impaired interaction with ATG16L1. Y->A%2CF;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:23376921,ECO:0000269|PubMed:27273576;Dbxref=PMID:23376921,PMID:27273576	
Q9BXS4	UniProtKB	Mutagenesis	268	268	.	.	.	Note=Does not affect ability to activate LC3. Y->W;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23376921;Dbxref=PMID:23376921	
Q9BXS4	UniProtKB	Mutagenesis	269	269	.	.	.	Note=No effect on interaction with ATG16L1. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27273576;Dbxref=PMID:27273576	
Q9BXS4	UniProtKB	Mutagenesis	272	272	.	.	.	Note=Does not affect ability to activate LC3. No effect on interaction with ATG16L1. E->A%2CD;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:23376921,ECO:0000269|PubMed:27273576;Dbxref=PMID:23376921,PMID:27273576	
Q9BXS4	UniProtKB	Mutagenesis	273	273	.	.	.	Note=No effect on interaction with ATG16L1. K->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27273576;Dbxref=PMID:27273576	
Q9BXS4	UniProtKB	Mutagenesis	277	277	.	.	.	Note=Impaired ability to activate LC3. Impaired interaction with ATG16L1. Y->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:23376921,ECO:0000269|PubMed:27273576;Dbxref=PMID:23376921,PMID:27273576	
Q9BXS4	UniProtKB	Mutagenesis	277	277	.	.	.	Note=Does not affect ability to activate LC3. Y->W%2CF;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23376921;Dbxref=PMID:23376921	
Q9BXS4	UniProtKB	Mutagenesis	278	278	.	.	.	Note=No effect on interaction with ATG16L1. G->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27273576;Dbxref=PMID:27273576	
Q9BXS4	UniProtKB	Mutagenesis	280	280	.	.	.	Note=Impaired ability to activate LC3. Impaired interaction with ATG16L1. L->A%2CV;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:23376921,ECO:0000269|PubMed:27273576;Dbxref=PMID:23376921,PMID:27273576	
Q9BXS4	UniProtKB	Sequence conflict	209	209	.	.	.	Note=Y->SD;Ontology_term=ECO:0000305;evidence=ECO:0000305	
